Zealand Pharma A/S (ZEAL.CO)
DKK 802.5
(0.44%)
DKK 802.5
(0.44%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -12.44 DKK | 40.48% |
| 2022 | -20.90 DKK | 12.0% |
| 2021 | -23.75 DKK | -7.61% |
| 2020 | -22.07 DKK | -30.51% |
| 2019 | -16.91 DKK | -189.28% |
| 2018 | 18.94 DKK | 293.86% |
| 2017 | -9.77 DKK | -54.34% |
| 2016 | -6.33 DKK | -28.14% |
| 2015 | -4.94 DKK | -72.13% |
| 2014 | -2.87 DKK | 64.66% |
| 2013 | -8.12 DKK | -604.35% |
| 2012 | 1.61 DKK | 419.35% |
| 2011 | 0.31 DKK | 105.39% |
| 2010 | -5.75 DKK | -26.93% |
| 2009 | -4.53 DKK | -137.17% |
| 2008 | -1.91 DKK | 38.59% |
| 2007 | -3.11 DKK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -4.67 DKK | -25.88% |
| 2024 Q1 | -3.71 DKK | 18.28% |
| 2023 Q4 | -4.54 DKK | -457.48% |
| 2023 FY | - DKK | 40.48% |
| 2023 Q2 | -5.50 DKK | -47.06% |
| 2023 Q3 | 1.27 DKK | 123.09% |
| 2023 Q1 | -3.74 DKK | 42.02% |
| 2022 Q2 | -9.77 DKK | -133.17% |
| 2022 Q4 | -6.45 DKK | -96.05% |
| 2022 FY | - DKK | 12.0% |
| 2022 Q1 | -4.19 DKK | 35.44% |
| 2022 Q3 | -3.29 DKK | 66.33% |
| 2021 Q4 | -6.49 DKK | -40.78% |
| 2021 Q1 | -5.77 DKK | 38.49% |
| 2021 Q3 | -4.61 DKK | 32.9% |
| 2021 FY | - DKK | -7.61% |
| 2021 Q2 | -6.87 DKK | -19.06% |
| 2020 FY | - DKK | -30.51% |
| 2020 Q2 | -1.57 DKK | 68.47% |
| 2020 Q3 | -5.76 DKK | -266.88% |
| 2020 Q4 | -9.38 DKK | -62.85% |
| 2020 Q1 | -4.98 DKK | 7.26% |
| 2019 Q3 | -3.44 DKK | 20.55% |
| 2019 Q4 | -5.37 DKK | -56.1% |
| 2019 FY | - DKK | -189.28% |
| 2019 Q1 | -4.13 DKK | -2.99% |
| 2019 Q2 | -4.33 DKK | -4.84% |
| 2018 Q2 | -4.14 DKK | -38.93% |
| 2018 FY | - DKK | 293.86% |
| 2018 Q1 | -2.98 DKK | 16.76% |
| 2018 Q4 | -4.01 DKK | -113.38% |
| 2018 Q3 | 29.96 DKK | 823.67% |
| 2017 Q2 | -3.66 DKK | -255.34% |
| 2017 FY | - DKK | -54.34% |
| 2017 Q3 | -1.48 DKK | 59.56% |
| 2017 Q4 | -3.58 DKK | -141.89% |
| 2017 Q1 | -1.03 DKK | -150.0% |
| 2016 Q4 | 2.06 DKK | 259.69% |
| 2016 Q1 | -3.06 DKK | -204.79% |
| 2016 FY | - DKK | -28.14% |
| 2016 Q3 | -1.29 DKK | 68.54% |
| 2016 Q2 | -4.10 DKK | -33.99% |
| 2015 Q2 | -3.33 DKK | -35.92% |
| 2015 FY | - DKK | -72.13% |
| 2015 Q1 | -2.45 DKK | 11.87% |
| 2015 Q4 | 2.92 DKK | 230.94% |
| 2015 Q3 | -2.23 DKK | 33.03% |
| 2014 Q3 | 0.75 DKK | 135.55% |
| 2014 Q2 | -2.11 DKK | -286.73% |
| 2014 Q1 | 1.13 DKK | 164.57% |
| 2014 FY | - DKK | 64.66% |
| 2014 Q4 | -2.78 DKK | -470.67% |
| 2013 Q3 | -1.53 DKK | 26.44% |
| 2013 Q2 | -2.08 DKK | 17.79% |
| 2013 Q1 | -2.53 DKK | -9.05% |
| 2013 FY | - DKK | -604.35% |
| 2013 Q4 | -1.75 DKK | -14.38% |
| 2012 Q3 | -0.03 DKK | -102.83% |
| 2012 FY | - DKK | 419.35% |
| 2012 Q4 | -2.32 DKK | -7633.33% |
| 2012 Q1 | 2.90 DKK | 441.18% |
| 2012 Q2 | 1.06 DKK | -63.45% |
| 2011 Q3 | -0.64 DKK | -130.48% |
| 2011 Q1 | -1.96 DKK | 28.47% |
| 2011 FY | - DKK | 105.39% |
| 2011 Q4 | -0.85 DKK | -32.81% |
| 2011 Q2 | 2.10 DKK | 207.14% |
| 2010 Q1 | -2.01 DKK | 0.0% |
| 2010 Q4 | -2.74 DKK | 14.91% |
| 2010 Q3 | -3.22 DKK | -251.89% |
| 2010 Q2 | 2.12 DKK | 205.47% |
| 2010 FY | - DKK | -26.93% |
| 2009 FY | - DKK | -137.17% |
| 2008 FY | - DKK | 38.59% |
| 2007 FY | - DKK | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| ALK-Abelló A/S | 2.20 DKK | 665.455% |
| Bavarian Nordic A/S | 19.23 DKK | 164.691% |
| Genmab A/S | 66.64 DKK | 118.667% |
| Gubra A/S | -2.93 DKK | -324.573% |
| Novo Nordisk A/S | 18.67 DKK | 166.631% |
| Orphazyme A/S | -0.74 DKK | -1581.081% |
| Pharma Equity Group A/S | -0.02 DKK | -54461.404% |